Entrada Therapeutics (TRDA) Income towards Parent Company (2020 - 2026)

Entrada Therapeutics' Income towards Parent Company history runs 7 years deep, the most recent figure standing at -$39.7 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company fell 128.93% year-over-year to -$39.7 million in Q1 2026; TTM through Mar 2026 was -$166.1 million, a 771.6% decrease from a year earlier, with the FY2025 full-year figure at -$143.7 million, down 319.01% from the prior year.
• Income towards Parent Company retreated to -$39.7 million in Q1 2026 per TRDA's latest filing, from -$39.2 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $55.0 million in Q2 2024 and bottomed at -$44.1 million in Q3 2025.
• The 5-year median for Income towards Parent Company is -$21.7 million (2022), against an average of -$12.9 million.
• Across the five-year window, Income towards Parent Company soared 452.05% in 2024 and sank 3563.48% in 2025, its largest moves.
• Year by year, Income towards Parent Company stood at -$24.6 million in 2022, then soared by 61.42% to -$9.5 million in 2023, then soared by 111.9% to $1.1 million in 2024, then sank by 3563.48% to -$39.2 million in 2025, then fell by 1.39% to -$39.7 million in 2026.
• Per Business Quant, the three latest TRDA Income towards Parent Company figures stand at -$39.7 million (Q1 2026), -$39.2 million (Q4 2025), and -$44.1 million (Q3 2025).